UBS Group’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $301K | Buy |
27,034
+990
| +4% | +$11K | ﹤0.01% | 5226 |
|
|
2025
Q1 | $320K | Buy |
26,044
+19,134
| +277% | +$235K | ﹤0.01% | 4979 |
|
|
2024
Q4 | $77.3K | Buy |
6,910
+2,825
| +69% | +$31.6K | ﹤0.01% | 5819 |
|
|
2024
Q3 | $28.5K | Sell |
4,085
-19
| -0.5% | -$132 | ﹤0.01% | 5944 |
|
|
2024
Q2 | $31K | Buy |
4,104
+2,404
| +141% | +$18.2K | ﹤0.01% | 5885 |
|
|
2024
Q1 | $22.4K | Buy |
+1,700
| New | +$22.4K | ﹤0.01% | 5707 |
|
|
2023
Q4 | – | Sell |
-55
| Closed | -$535 | – | 8411 |
|
|
2023
Q3 | $535 | Buy |
+55
| New | +$535 | ﹤0.01% | 7277 |
|
|
2023
Q2 | – | Sell |
-2,623
| Closed | -$12.2K | – | 8215 |
|
|
2023
Q1 | $12.2K | Buy |
2,623
+1,071
| +69% | +$4.97K | ﹤0.01% | 6364 |
|
|
2022
Q4 | $2.31K | Sell |
1,552
-621
| -29% | -$925 | ﹤0.01% | 8501 |
|
|
2022
Q3 | $8K | Buy |
+2,173
| New | +$8K | ﹤0.01% | 7632 |
|
|
2022
Q2 | – | Sell |
-101
| Closed | -$1K | – | 9558 |
|
|
2022
Q1 | $1K | Sell |
101
-3,602
| -97% | -$35.7K | ﹤0.01% | 8831 |
|
|
2021
Q4 | $38K | Buy |
+3,703
| New | +$38K | ﹤0.01% | 6070 |
|
|
2021
Q3 | – | Sell |
-2,563
| Closed | -$61K | – | 8632 |
|
|
2021
Q2 | $61K | Buy |
+2,563
| New | +$61K | ﹤0.01% | 5197 |
|